Plataforma BIOBADASER III

Registro Español de Acontecimientos Adversos de Terapias Dirigidas en Enfermedades Reumáticas

Biobadaser Fase III

Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

16/11/2023

Sánchez-Piedra C, Expósito L, VELA P, Moreno Ramos M, Campos C, Bohorquez C, Calvo J, Plaza Z, Domínguez M, Diaz-Gonzalez J

ACR 2023

Sánchez-Piedra C, Expósito L, VELA P, Moreno Ramos M, Campos C, Bohorquez C, Calvo J, Plaza Z, Domínguez M, Diaz-Gonzalez J. Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/real-world-persistence-of-initial-targeted-therapy-strategy-in-monotherapy-versus-combination-therapy-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis/

https://acrabstracts.org/abstract/real-world-persistence-of-initial-targeted-therapy-strategy-in-monotherapy-versus-combination-therapy-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis/